Evidence map›Paper›PMID 26182239›Full record

ArticleNature protocols2015

Quantification of nascent transcription by bromouridine immunocapture nuclear run-on RT-qPCR.

Thomas C Roberts, Jonathan R Hart, Minna U Kaikkonen, Marc S Weinberg, Peter K Vogt, Kevin V Morris

Abstract read
In one paragraph

Article in Nature protocols, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. YTHDC1 Is Essential for Postnatal Liver Development and Homeostasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Smoking and tetramer tryptase accelerate intervertebral disc degeneration by inducing METTL14-mediated DIXDC1 mMolecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. ExploringPharmaceutics · 2023
    Article
  17. Review
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Thomas C Roberts1] Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA. [2] Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK. [3] Sanford-Burnham Medical Research Institute, Development, Aging and Regeneration Program, La Jolla, California, USA.
Jonathan R HartDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Minna U KaikkonenDepartment of Biotechnology and Molecular Medicine, A.I. Virtanen Institute, University of Eastern Finland, Kuopio, Finland.
Marc S Weinberg1] Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA. [2] Antiviral Gene Therapy Research Unit, Department of Molecular Medicine and Haematology, University of the Witwatersrand Medical School, Johannesburg, South Africa. [3] HIV Pathogenesis Research Unit, Department of Molecular Medicine and Haematology, University of the Witwatersrand Medical School, Johannesburg, South Africa.
Peter K VogtDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Kevin V Morris1] Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA. [2] School of Biotechnology and Biomedical Sciences, University of New South Wales, Sydney, New South Wales, Australia.

Funding

Targeted Delivery Vechicles for OligonucleotidesP01AI099783 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI AKKINA, RAMESH · 2012 to 2016
$7.4M
Medical Research CouncilNIAID NIH HHS P01 AI099783
6 · The paper itself

Abstract

Nuclear run-on (NRO) is a method that measures transcriptional activity via the quantification of biochemically labeled nascent RNA molecules derived from nuclear isolates. Widespread use of this technique has been limited because of its technical difficulty relative to steady-state total mRNA analyses. Here we describe a detailed protocol for the quantification of transcriptional activity in human cell cultures. Nuclei are first isolated and NRO transcription is performed in the presence of bromouridine. Labeled nascent transcripts are purified by immunoprecipitation, and transcript levels are determined by reverse-transcription quantitative PCR (RT-qPCR). Data are then analyzed using standard techniques described elsewhere. This method is rapid (the protocol can be completed in 2 d) and cost-effective, exhibits negligible detection of background noise from unlabeled transcripts, requires no radioactive materials and can be performed from as few as 500,000 nuclei. It also takes advantage of the high sensitivity, specificity and dynamic range of RT-qPCR.

Indexed as

Reverse Transcriptase Polymerase Chain ReactionTranscription, GeneticBromouracilCell LineHigh-Throughput Nucleotide SequencingHumansImmunoprecipitationUridine5-bromouridineBromouracilUridine

Identifiers

PMID26182239
PMCPMC4790731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.